Hi all,
I am hoping to create awareness for an article we recently published on subcutaneous (SC) administration of mAbs in the Clinical Pharmacology and Therapeutics journal. This review presents learnings from key constituents of the SC mAb development pathway, including pharmacology, administration variables, immunogenicity, and delivery devices. The immunogenicity section compared ADA incidence data for 20 therapeutic proteins that were administered both intravenously (IV) and SC. Overall, our analysis identified that ADA incidence was found to be generally comparable across IV and SC routes.
Here is the link to the article: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3150
------------------------------
Kamalika Mukherjee
Principal Scientist
Regeneron Pharmaceuticals
Tarrytown NY
[email protected]
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------